Maarten Cozijnsen

72 newly diagnosed and untreated, RNA-results are unaffected by previous treatments. Furthermore, since infliximab treatment is assumed to result in more endoscopic remission, comparison of the responses to both treatments allowed us to study immune pathways that drive endoscopic remission. Results of this pilot study will be studied further upon completion of the RCT. 1